ArticleNeuro-oncology2018
The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.
Article in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 210 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
210 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- EANS-EANO guidelines on the extent of resection in gliomas.Neuro-oncology · 2026Guideline
- Impact of awake mapping on extent of resection and neurological outcomes of Low-grade gliomas: a systematic review and Meta-analysis.Neurosurgical review · 2025Pooled it
- Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of surgery in the management of patients with diffuse low grade glioma: update.Journal of neuro-oncology · 2025Pooled it
- SEOM-GEINO clinical guidelines for grade 2 gliomas (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Intraoperative mapping of the right hemisphere: a systematic review of protocols that evaluate cognitive and social cognitive functions.Frontiers in psychology · 2024Pooled it
- Extent of resection in diffuse low-grade gliomas and the role of tumor molecular signature-a systematic review of the literature.Neurosurgical review · 2021Pooled it
- Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis.European radiology · 2020Pooled it
- IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis.Neurosurgical review · 2020Pooled it
- Trial
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.The New England journal of medicine · 2023Trial
- Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.The Lancet. Oncology · 2021Trial
- Comparison of Outcomes between Supramaximal Resection and Gross Total Resection for High-Grade Gliomas: A Prospective Study from a Tertiary Care Centre.Asian journal of neurosurgery · 2026Article
- Surgical characteristics and postoperative outcomes in a retrospective cohort study of patients with molecularly defined oligodendroglioma.Journal of neuro-oncology · 2026Article
- Multidisciplinary recommendations for routine follow-up of isocitrate dehydrogenase‑mutant glioma in 2026: Adapting clinical practice to the molecular era.Neuro-oncology practice · 2026Review
- Core-based voxel-wise T2-FLAIR mismatch analysis for differentiation of IDH-mutant astrocytomas from oligodendrogliomas.Neuroradiology · 2026Article
- Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management.Current treatment options in oncology · 2026Review
- Contemporary surgical strategies for resection of intracranial gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Association of CDKN2A/B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma.Annals of clinical and translational neurology · 2026Article
- Gyriform infiltration indicates tumor invasion burden of isocitrate dehydrogenase 1/2-wildtype gliomas.Brain tumor pathology · 2026Article
150 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extensive resections in low-grade glioma (LGG) are associated with improved overall survival (OS). However, World Health Organization (WHO) classification of gliomas has been completely revised and is now predominantly based on molecular criteria. This requires reevaluation of the impact of surgery in molecularly defined LGG subtypes. Methods: We included 228 adults who underwent surgery since 2003 for a supratentorial LGG. Pre- and postoperative tumor volumes were assessed with semiautomatic software on T2-weighted images. Targeted next-generation sequencing was used to classify samples according to current WHO classification. Impact of postoperative volume on OS, corrected for molecular profile, was assessed using a Cox proportional hazards model. Results: Median follow-up was 5.79 years. In 39 (17.1%) histopathologically classified gliomas, the subtype was revised after molecular analysis. Complete resection was achieved in 35 patients (15.4%), and in 54 patients (23.7%) only small residue (0.1-5.0 cm3) remained. In multivariable analysis, postoperative volume was associated with OS, with a hazard ratio of 1.01 (95% CI: 1.002-1.02; P = 0.016) per cm3 increase in volume. The impact of postoperative volume was particularly strong in isocitrate dehydrogenase (IDH) mutated astrocytoma patients, where even very small postoperative volumes (0.1-5.0 cm) already negatively affected OS. Conclusion: Our data provide the necessary reevaluation of the impact of surgery in molecularly defined LGG and support maximal resection as first-line treatment for molecularly defined LGG. Importantly, in IDH mutated astrocytoma, even small postoperative volumes have negative impact on OS, which argues for a second-look operation in this subtype to remove minor residues if safely possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.